Has Stephen Monteith, MD received payments from drug or device companies?

Yes. Drug and device makers reported $151,452 in general payments to Stephen Monteith, MD across 154 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stephen Monteith, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stephen Monteith, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stephen Monteith, MD

Neurological Surgery · Seattle, WANPI 1689868119

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $122,625 of the $151,452 with a category attached, or 81.0%. Microvention, Inc. accounts for 98.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $41,510 and has fallen 60.8% since, to $16,275 in 2025. Among neurological surgery clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$151,452in general payments, 2019–2025

Across 154 payments — averaging $983.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Microvention, Inc.$149K
Balt USA, LLC$2K
Rapid Medical Ltd$229
Siemens Medical Solutions USA, Inc.$151
Integra Lifesciences Corporation$136
Boston Scientific$121
plus $131 from 3 others

$273,761in research payments, 2019–2025

Across 37 payments — averaging $7398.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Balt USA, LLC$274K

What the payments were for

Consulting fees$12,5178%
Speaking & faculty fees$122,62581%
Travel & lodging$11,9838%
Food & beverage$4,3273%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Microvention, Inc.	115	$148,709
Balt USA, LLC	26	$1,975
Rapid Medical Ltd	5	$229
Siemens Medical Solutions USA, Inc.	1	$151
Integra Lifesciences Corporation	1	$136
Boston Scientific	1	$121
Medtronic	2	$56
Globus Medical	2	$55
Qapel Medical Inc	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

WEB$76,093
WEB Aneurysm Embolization System$63,903
STENT$1,247
Barricade Coil System$536
MAGIC Catheter$536
Optima Thermal Coil System$536
Sofia$401
LVIS Jr.$385
Optima Coil System$316
Scepter XC Balloon Catheter$236
TIGERTRIEVER 17 REVASCULARIZATION DEVICE$160
COMANECI 17$160
CorPath Imaging System$151
LVIS$149
HydroFrame Coil$141
HydroSoft 3D Coil$141
HydroSoft Coil$141
CODMAN CERTAS$136
CUSA CLARITY$136
CODMAN HAKIM$136

How this compares

$151,452 in reported general payments places this provider in the 95th percentile of 175 neurological surgery providers in Washington.

See all neurological surgery providers in Washington →

Medicare billing

Part B allowed, 2024

$154,442

Medicare patients

166

Services billed

401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ClopidogrelClopidogrel Bisulfate	38	$403

Paid to pharmacies, not to this prescriber.

Other neurological surgery in Seattle

Rod OskouianSeattle$2.4M
Christoph HofstetterSeattle$768K
Jean-Christophe LevequeSeattle$120K
Vijay YanamadalaSeattle$85K
Hoan Vu TranSeattle$78K
Martin RutkowskiSeattle$62K
Bailey ZampellaSeattle$38K
Melanie WalkerSeattle$38K
Elias EliasSeattle$35K
Ryder GwinnSeattle$35K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →